199806-02-5

Basic information

• Product Name: ETHYL 6-TERT-BUTYL-2-METHYLNICOTINATE
• Synonyms: ETHYL 6-TERT-BUTYL-2-METHYLNICOTINATE;(5-amino-1H-indol-2-yl)methanol;5-amino-2-hydroxymethylindole
• CAS NO: 199806-02-5
• Molecular Formula: C9H10N2O
• Molecular Weight: 162.19
• Mol File: 199806-02-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 6-TERT-BUTYL-2-METHYLNICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 6-TERT-BUTYL-2-METHYLNICOTINATE(199806-02-5)
• EPA Substance Registry System: ETHYL 6-TERT-BUTYL-2-METHYLNICOTINATE(199806-02-5)

Safety Data

• Hazardous Substances Data: 199806-02-5(Hazardous Substances Data)

Upstream product

• 16732-57-3 5-nitro-indole-2-carboxylic acid ethyl ester 
• 199805-99-7 (5-nitro-1H-indol-2-yl)methanol 

Relevant articles and documents

NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES

This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Synthesis and preliminary biological evaluations of CC-1065 analogues: Effects of different linkers and terminal amides on biological activity

CC-1065 analogues possessing a biologically active CBI functional group and amide-substituted indole and benzofuran were synthesized. The IC50 values of compounds 26, bearing two indoles, and 25, bearing only one indole, are 0.4 and 3 nM, respectively, against U937 leukemia cells in vitro. The IC50 values of compounds 28, bearing a butyramino group, and 27, bearing an acetamino group, are 0.008 and 0.4 nM, respectively, against U937 leukemia cells in vitro. Compound 29, bearing a double-bond linker, is about 4-fold more potent than 25, bearing no double-bond linker. Compound 26 is highly potent against all cell lines tested in the NCI in vitro screening with IC50 values in the 0.1-5 nM range for most cell lines. Compounds 26 and 30 are highly active against L1210 leukemia in mice. Compound 26 is also active against B16BL6 melanoma in mice. Most importantly, 26 and 30 are not myelosuppressive at therapeutically effective doses. The mechanism of tumor cell death is through induction of apoptosis, and is accompanied by DNA fragmentation.